Clinical Trial Update: A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lazertinib as consolidation therapy after chemoradiation in locally advanced, unresectable EGFR-mutant non-small cell lung cancer (Stag…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer
• Non-squamous Non-small Cell Lung Cancer

Drugs mentioned

• Lazertinib (lazertinib)

Snippet

Sponsor: Sung Yong Lee | Conditions: Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN